Ar­cus and As­traZeneca part­ner on a high stakes an­ti-TIG­IT/PD-L1 PhI­II can­cer study, look­ing to im­prove on a stan­dard of care

For As­traZeneca, the PA­CIF­IC tri­al in Stage III non-small cell lung can­cer re­mains one of the big tri­umphs for As­traZeneca’s on­col­o­gy R&D group. It not on­ly made their PD-L1 Imfinzi a fran­chise play­er with a sol­id ad­vance in a large niche of the lung can­cer mar­ket, the study — which con­tin­ues to of­fer da­ta on the long-range ef­fi­ca­cy of their drug — al­so helped salve the vi­cious sting of the fail­ure of the CT­LA-4 com­bo in the MYS­TIC study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER